Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer

P F Conte, Pierfranco Conté, Sertoli MR, M R Sertoli, Bruzzone M, M Bruzzone, A Rubagotti, Rubagotti A, Rosso R, R Rosso, Bentivoglio G, G Bentivoglio, Conio A, A Conio, Pescetto G, G Pescetto
Gynecologic Oncology · 1985 · vol. 20(3) , pp. 290–7 · doi:10.1016/0090-8258(85)90210-0 · PMID:2982705
Other OA: green CC-BY-4.0
🔓 Open OA copy View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-13 ⓘ

This study evaluated a cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy regimen in patients with advanced ovarian cancer, reporting response rates of 69.2% in untreated and 50% in pretreated individuals alongside manageable toxicity profiles.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A combination chemotherapy including cisplatin, 25 mg/m2 on Days 1,8; methotrexate, 30 mg/m2 on Day 1; and 5-fluorouracil, 600 mg/m2 on Day 1 has been evaluated in 28 previously untreated and 10 pretreated patients with advanced ovarian cancer after debulking surgery when feasible. The pathological response rates (complete + partial responses) were 69.2 and 50% in untreated and pretreated patients, respectively. Overall 24-month survival and progression-free survival (PFS) are 19.2 and 10.9%, respectively. A significant difference in survival and PFS is evident between patients with less and more than 2 cm residual disease and between responders (CR + PR) versus nonresponders. No renal toxicity was induced and no cycles had to be delayed because of hemathologic toxicity.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Combined Chemotherapy Protocols Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma, Mucinous Adenocarcinoma, Mucinous Adenocarcinoma, Mucinous Adult Adult Aged Aged Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols Carcinoma Carcinoma Carcinoma Cisplatin Cisplatin Cisplatin

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
pubmed
last seen: 2026-10-08T21:22:15.942320+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine